Sanofi India Faces Rs 72.77 Crore Tax Demand Notice

Proposed tax liability: Rs 36.39 crore; Proposed penalty: Rs 36.39 crore.

Reader Takeaway: Company contests product classification; maintains no material financial impact expected from ongoing GST tax dispute.

What just happened

Sanofi India Limited has received a Show Cause Notice (SCN) from the Additional Commissioner of CGST and CX, Mumbai East. The regulatory body has raised a concern regarding the classification of products for the financial year 2020-21, specifically questioning the application of a 5% GST rate versus a 12% rate.

Why this matters

The notice seeks a total potential demand of Rs 72.77 crore, which comprises the base tax liability of Rs 36.39 crore and an equal amount in proposed penalties. While this is a significant sum, the company has communicated that it is currently reviewing the notice with tax advisors to prepare a formal response within the mandated timeframe.

What changes now

The company has stated it does not expect this notice to result in any material adverse impact on its business operations or financial health. Investors should monitor future exchange filings for updates on the adjudication process and any final orders issued by the tax department.

Risks to watch

Regulatory and tax disputes in the pharmaceutical sector can often be time-consuming. Any escalation in the adjudication process or an adverse ruling that necessitates a provision or cash outflow could impact immediate liquidity or balance sheet positioning if the company fails to successfully defend its tax classification stance.

What to track next

The primary focus for shareholders remains the company's formal reply to the CGST authorities and the subsequent feedback or hearing schedule set by the Additional Commissioner of Mumbai East.